SEMA (GLP-1) 10 mg
research-grade
lyophilized peptide powder
supplied in a glass vial. SEMA (GLP-1) is a long-acting synthetic analog of human glucagon-like peptide-1 (GLP-1),
engineered with sequence substitutions and acylation to enhance stability and duration of action, and studied as a potent
GLP-1 receptor agonist in experimental metabolic research models.
Research Use Only:
All products are intended exclusively for laboratory and scientific research. Not for human or veterinary use.
Purity
High-purity research grade
Form
Lyophilized peptide powder
Content
10 mg SEMA (GLP-1) per vial
Packaging
Glass vial with sterile closure
Storage
Store lyophilized at 2–8 °C (desiccated, protect from light)
Molecular formula
C187H291N45O59
Molecular weight
~4113.6 g·mol⁻¹
Sequence / structure
H-His-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-{diacid-C18-γGlu-(AEEA)2}-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
In laboratory workflows, lyophilized research peptides are typically handled with suitable sterile diluents such as bacteriostatic water (BAC).
For a compatible research-only solvent, see
Bacteriostatic water – 10 ml
.
Research Overview
SEMA (GLP-1) is a long-acting GLP-1 receptor agonist based on the human incretin hormone GLP-1 and modified with amino acid substitutions
and fatty-acid acylation to increase resistance to enzymatic degradation. In experimental in vitro and in vivo models it is used to
investigate GLP-1 receptor signaling and its impact on glucose homeostasis, insulin and glucagon dynamics, appetite-related pathways
and gastrointestinal motility under controlled laboratory conditions.
Primary Research Areas
-
GLP-1 receptor agonism:
used in models evaluating GLP-1 receptor activation, downstream cAMP signaling and effects on pancreatic islet function and peripheral tissues.
-
Glucose-dependent insulin secretion:
applied in research on glucose-stimulated insulin release, β-cell function and glycemic excursions in normoglycemic and diabetogenic setups.
-
Glucagon suppression and hepatic output:
investigated in preclinical systems studying how GLP-1 signaling modulates α-cell glucagon secretion and hepatic glucose production.
-
Appetite regulation and satiety pathways:
used in models exploring central and peripheral mechanisms of appetite, food intake behavior and satiety-related neuroendocrine circuits.
-
Metabolic and cardiometabolic endpoints:
included in broader metabolic research on body weight regulation, adiposity, lipid profiles and cardiovascular risk markers in response to GLP-1 pathway modulation.
